Ph 2 Elacestrant in ER Positive Uterine Sarcomas

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2026
This study is to evaluate the efficacy and safety of elacestrant, in participants with advanced estrogen receptor (ER)-positive uterine sarcomas. The name of the study drug involved in this research study is: -Elacestrant (a type of selective estrogen receptor degrader)
Epistemonikos ID: 1990e6cfd182c624c6499970efbf14c00c77077a
First added on: Mar 13, 2026